A patient has undergone nephrectomy for clear-cell renal-cell carcinoma and is considered at increased risk for recurrence. You are reviewing evidence on adjuvant pembrolizumab with or without belzutifan.
What does the evidence in this abstract support regarding adjuvant pembrolizumab-belzutifan compared with pembrolizumab-placebo after nephrectomy?